Shimadzu: Mass Spectrometry, New Cancer Immunotherapy Development: Providence Cancer Institute
Shimadzu / Providence Cancer Institute
Shimadzu Corporation will start full-scale joint research with Providence Cancer Research Center of the United States.
Shimadzu will work with the Providence Cancer Institute, Oregon, in the United States, to advance research and development of a new cancer immunotherapy using mass spectrometry technology.
Cancer immunotherapy: head and neck, lung, kidney cancer
This study targets cancers in the head and neck, lungs, kidneys, and more.
Joint research: Shimadzu / Providence
In joint research
Individual cancer markers (antigens) in immunotherapy,
We will develop technology to identify the pharmacokinetics of therapeutic drugs.
In January 2018, Shimadzu Scientific Instruments, Inc.’s Innovation Center started research.
In October 2018, Shimadzu Bioscience Research Partnership) was established in Bothell, Washington.
In August 2019, delivered a liquid chromatograph mass spectrometry system “ Nexera Mikros ” compatible with micro flow rate,
In August 2019, we delivered our latest analyzers such as the LCMS-9030, a liquid chromatograph mass spectrometer.
Launched “System for Direct Identification of Cancer Antigens“.
Mass spectrometry: Technology utilization
Shimadzu acquires antigen information that is directly recognized by immunity using our mass spectrometry technology.
Providence will integrate the gene and cell information with which it is good at analysis, and will lead to the development of new treatments.
Our strength in mass spectrometry technology is
This technology measures a large number of components that are important in drug discovery and clinical fields at once.
Joint Research: Shimadzu / Providence
Applying technologies and products such as the pretreatment kit “nSMOL Antibody BA Kit” *
Accurately identify cancer antigens recognized by the individual’s immune system,
It is to analyze the dynamics of antibody drugs precisely.
A three-year research plan from 2018 is planned.
We aim to introduce clinical trials at clinical sites such as Providence.
2019 | Shimadzu Corporation